Why is Medico Remedies Ltd falling/rising?

Recent Price Movement and Market Context

Medico Remedies Ltd closed at ₹48.00 on 09 January, down by ₹0.46 or 0.95% from the previous session. This decline continues a five-day losing streak, during which the stock has fallen by 5.25%. This underperformance is more pronounced than the broader Sensex index, which declined by 2.55% over the same one-week period. The stock’s year-to-date return also trails the benchmark, with a 5.06% drop compared to Sensex’s 1.93% fall.

Over the longer term, the stock has struggled relative to the market. While the Sensex has delivered a 7.67% gain over the past year, Medico Remedies has declined by 21.18%. Even over three years, the stock is down 28.20%, contrasting sharply with the Sensex’s 37.58% rise. However, the five-year return remains impressive at 1180%, significantly outpacing the benchmark’s 71.32% gain, highlighting the company’s strong historical growth trajectory.

Technical Indicators and Trading Activity

From a technical perspective, the stock’s current price sits above its 100-day moving average but remains below its 5-day, 20-day, 50-day, and 200-day moving averages. This positioning suggests short- to medium-term weakness despite some longer-term support. Additionally, investor participation appears to be waning, with delivery volume on 08 January falling by 38.58% compared to the five-day average, signalling reduced enthusiasm or caution among shareholders. Liquidity remains adequate for moderate trade sizes, with the stock able to handle trades worth approximately ₹0.02 crore based on recent average traded values.

Fundamental Strengths Amid Price Weakness

Despite the recent price softness, Medico Remedies demonstrates several positive fundamental attributes. The company boasts a high management efficiency, reflected in a return on capital employed (ROCE) of 15.04%, which is a robust indicator of effective capital utilisation. Furthermore, the firm maintains a strong debt servicing capacity, with a low Debt to EBITDA ratio of 0.89 times, suggesting manageable leverage and financial stability.

Operationally, the company has reported positive results for three consecutive quarters. Notably, the half-year ROCE peaked at 20.65%, while quarterly profit after tax (PAT) reached ₹2.57 crore, marking a substantial growth of 65.8%. The debtors turnover ratio also improved to 2.99 times, indicating efficient receivables management. These metrics underscore the company’s improving profitability and operational discipline.

Valuation metrics further support a cautious optimism. With a ROCE of 15.8 and an enterprise value to capital employed ratio of 5.3, the stock appears fairly valued and trades at a discount relative to its peers’ historical averages. The company’s profits have risen by 47.8% over the past year, even as the stock price declined, resulting in a price-to-earnings-to-growth (PEG) ratio of 0.7, which may indicate undervaluation from a growth perspective.

Balancing Market Sentiment and Fundamentals

The current decline in Medico Remedies’ share price appears to be driven primarily by short-term market dynamics and investor caution rather than fundamental weaknesses. The stock’s underperformance relative to the Sensex and its own moving averages suggests that traders are hesitant, possibly influenced by broader sector trends or profit-taking after recent gains. The falling delivery volumes reinforce this narrative of reduced investor participation.

However, the company’s solid financial metrics, consistent profit growth, and reasonable valuation provide a counterbalance to the recent price weakness. Investors may view the current dip as a consolidation phase within a longer-term growth story, especially given the company’s strong five-year returns and improving operational efficiency.

In summary, while Medico Remedies Ltd’s stock price has been falling in the short term, the underlying business fundamentals remain sound. The decline reflects a combination of technical pressures and cautious market sentiment rather than deteriorating company performance, suggesting that the stock may warrant a hold position for investors monitoring both value and growth potential.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →